Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is effective against B-cell malignancies but limited by tumor microenvironment (TME) immunosuppression and toxicities like cytokine release syndrome (CRS) and neurotoxicity.
• The TME contains immunosuppressive cells and factors that hinder CAR T-cell function, particularly in solid tumors.
• Current CAR T-cell therapies face challenges in achieving durable responses and managing adverse events.

Purpose of the Study:

• To discuss the mechanisms by which the TME antagonizes CAR T-cells.
• To explore innovative immunotherapy strategies designed to overcome TME-mediated resistance.
• To analyze how novel approaches may impact adverse events and expand CAR T-cell therapy applications.

Main Methods:

• Review of existing literature on CAR T-cell therapy, TME components, and emerging immunotherapies.
• Discussion of mechanisms of TME-induced immunosuppression against CAR T-cells.
• Analysis of combinatorial strategies and 'armored' CAR T-cells.

Main Results:

• The TME significantly suppresses CAR T-cell efficacy through various cellular and acellular components.
• Novel strategies like armored CAR T-cells and combinatorial therapies are being developed to enhance CAR T-cell function.
• These advanced strategies may increase efficacy but also potentially elevate the risk of adverse events.

Conclusions:

• Overcoming TME-mediated immunosuppression is crucial for durable CAR T-cell responses.
• Innovative immunotherapies are needed to enhance CAR T-cell efficacy and broaden their application to diverse cancers.
• Precise immunomodulation is key to balancing improved tumor control with mitigated toxicities for future CAR T-cell therapies.